OSU-T315 is a potent, orally active ILK (integrin-linked kinase) inhibitor with IC50 of 0.6 uM.
OSU-T315 exhibits high in vitro potency against a panel of prostate and breast cancer cell lines (IC50=1-2.5 uM) with no effect on normal epithelial cells.
OSU-T315 facilitates the dephosphorylation of Akt at Ser-473 and other ILK targets, including GSK-3β and myosin light chain.
OSU-T315 suppresses the expression of the transcription/translation factor YB-1 and HER2, EGFR in PC-3 cells, induces autophagy and apoptosis.
OSU-T315 demonstrates in vivo efficacy in suppressing PC-3 xenograft tumor growth; orally active.
